Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

577
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
577

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same authorSame journal

Sutimlimab for cold agglutinin disease: an updated perspective from approval to real-world clinical treatment.

Expert review of hematology·2026
Same author

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.

American journal of hematology·2026
Same author

Navigating the paroxysmal nocturnal hemoglobinuria (PNH) landscape.

Clinical advances in hematology & oncology : H&O·2025
Same author

Monotherapy with upstream or alternative pathway inhibitors.

Clinical advances in hematology & oncology : H&O·2025
Same author

Dual therapy: danicopan as add-on therapy to C5 inhibitors.

Clinical advances in hematology & oncology : H&O·2025
Same author

Practical approach to managing PNH: Q&A.

Clinical advances in hematology & oncology : H&O·2025

相关实验视频

Updated: Jul 28, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

寒冷的凝聚蛋白疾病的辅助导向治疗: sutimlimabb.

Catherine M Broome1

  • 1Division of Hematology, MedStar Georgetown University Hospital, Washington, DC, USA.

Expert review of hematology
|May 31, 2023
PubMed
概括

苏提利马布为一种罕见的自身免疫性疾病 - - 寒冷凝聚素疾病 (CAD) 提供了一种新的治疗方法. 这种疗法有效地减少了红细胞的破坏,并改善了患者的福祉.

科学领域:

  • 免疫学 免疫学 免疫学
  • 血液学 血液学 血液学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 感冒凝聚蛋白疾病 (CAD) 是一种罕见的自身免疫性血清性贫血,其特征是针对红细胞的IgM抗体.
  • 在CAD中血液溶解是由IgM-抗原复合体激活的经典补充通路驱动的.

研究的目的:

  • 为了审查 sutimlimab. 的药物概况.
  • 总结了在CAD中使用stimlimab的第三阶段研究中的疗效和安全性数据.
  • 为了突出sutimlimab在CAD管理和正在进行的现实世界证据收集中的作用.

主要方法:

  • 对CAD中stimlimab的第三阶段临床试验数据的审查.
  • 对疗效终点的分析,包括血红蛋白水平和溶血标志物.
  • 评估安全概况和改善生活质量的评估.

主要成果:

  • 苏提利马布在血红蛋白和血液溶解标志物中表现出快速和持续的改善.
  • 患者经历了疲劳的显著减少和生活质量的改善.
  • 在患有CAD的患者中,sutimlimab的耐受性通常很好.

结论:

关键词:
感冒凝聚素疾病是一种疾病.补充C1ss是一个补充.补充导向的疗法是指导疗法.血液溶解 血液溶解生活质量生活的质量.顺便说一下,这是一个令人难以置信的.

更多相关视频

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.7K
Depletion of Specific Cell Populations by Complement Depletion
06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

22.2K

相关实验视频

Last Updated: Jul 28, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.7K
Depletion of Specific Cell Populations by Complement Depletion
06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

22.2K
  • 苏提利马布为CAD管理提供了一种经批准的治疗选择,改善了临床结果.
  • 它的好处超越了血液溶解抑制,以提高患者的整体幸福感.
  • 来自CADENCE注册表的现实世界证据将进一步评估stimlimab的有效性和安全性.